Literature DB >> 8844481

Effect of a cholecystokinin receptor antagonist (loxiglumide) on gallbladder contractile function in guinea pigs.

K Tsubo1, M Arai, H Omachi, K Mitamura.   

Abstract

We evaluated the effect of the specific cholecystokinin (CCK) receptor antagonist, loxiglumide, on gallbladder contractile function in guinea pigs. Five mg/kg body weight (BW) of loxiglumide was administered orally to guinea pigs once a day for 3 days. We then investigated gallbladder contractile function and plasma CCK concentrations in the guinea pigs. Maximal gallbladder pressure induced by cerulein was significantly depressed on the 1st and 3rd days following loxiglumide administration. On the 1st day, the plasma CCK concentration was significantly increased compared with that of the control group during fasting and 15 min after the administration of an intraduodenal test meal. These results suggest that the disturbed gallbladder contraction is due to the competitive inhibition of CCK by loxiglumide. Gallbladder contractile function in guinea pigs is depressed by loxiglumide; however, this effect is reversible after short-term loxiglumide administration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8844481     DOI: 10.1007/bf02355060

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  14 in total

1.  Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man.

Authors:  P Hildebrand; C Beglinger; K Gyr; J B Jansen; L C Rovati; M Zuercher; C B Lamers; I Setnikar; G A Stalder
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

2.  Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas.

Authors:  M Otsuki; M Fujii; T Nakamura; Y Okabayashi; S Tani; T Fujisawa; M Koide; S Baba
Journal:  Dig Dis Sci       Date:  1989-06       Impact factor: 3.199

3.  Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.

Authors:  R S Chang; V J Lotti
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

4.  Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models.

Authors:  S Tani; Y Okabayashi; T Nakamura; M Fujii; H Itoh; M Otsuki
Journal:  Pancreas       Date:  1990-05       Impact factor: 3.327

5.  Plasma cholecystokinin responses after ingestion of liquid meal and intraduodenal infusion of fat, amino acids, or hydrochloric acid in man: analysis with region specific radioimmunoassay.

Authors:  S Himeno; S Tarui; S Kanayama; T Kuroshima; Y Shinomura; C Hayashi; K Tateishi; K Imagawa; E Hashimura; T Hamaoka
Journal:  Am J Gastroenterol       Date:  1983-11       Impact factor: 10.864

6.  Anticholecystokinin activities of loxiglumide.

Authors:  I Setnikar; M Bani; R Cereda; R Chisté; F Makovec; M A Pacini; L Revel
Journal:  Arzneimittelforschung       Date:  1987-10

7.  Differential effects of atropine and a cholecystokinin receptor antagonist on pancreatic secretion.

Authors:  G Adler; M Reinshagen; I Koop; B Göke; A Schafmayer; L C Rovati; R Arnold
Journal:  Gastroenterology       Date:  1989-04       Impact factor: 22.682

8.  Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop.

Authors:  S Tani; H Itoh; M Koide; Y Okabayashi; M Otsuki
Journal:  Pancreas       Date:  1993-01       Impact factor: 3.327

9.  Production of rabbit antibody specific for amino-terminal residues of cholecystokinin octapeptide (CCK-8) by selective suppression of cross-reactive antibody response.

Authors:  E Hashimura; F Shimizu; T Nishino; K Imagawa; K Tateishi; T Hamaoka
Journal:  J Immunol Methods       Date:  1982-12-30       Impact factor: 2.303

10.  Effects of loxiglumide on gallbladder emptying in healthy volunteers.

Authors:  C Niederau; T Heintges; L Rovati; G Strohmeyer
Journal:  Gastroenterology       Date:  1989-11       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.